A remarkably low translation rate of 0.14% of colorectal cancer (CRC) biomarkers have been approved for patient care. The lack of approval and commercialization of CRC biomarkers might be due to a lack of follow-up research and the quality of journals where the findings are reported, according to a recent article in Frontiers in Medicine .

CRC remains one of the leading causes of cancer-related deaths worldwide, yet early detection dramatically improves survival. In recent years, researchers have identified a growing number of molecular biomarkers with the potential to transform CRC screening and diagnosis. The challenge lies not in discovery but in translation, moving promising biomarkers from the laboratory into clinical practice.

Evidence demonstrates that early diagnosis significa

See Full Page